No Data
No Data
No Data
No Data
No Data
Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
Additional data from the Phase 2 ARCHER trial demonstrating protection of visual acuity and anatomical structure following ANX007 treatment will be featured as an oral presentation New preclinical dat
GlobeNewswireMay 1 20:00
Cantor Fitzgerald Corp.: Annexon (ANNX.US) shareholding rating confirmed.
Cantor Fitzgerald Corp.: Annexon (ANNX.US) shareholding rating confirmed.
Zhitong FinanceApr 24 21:01
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
BRISBANE, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for people living with devastating
GlobeNewswireApr 17 04:05
Turnstone Biologics Appoints William Waddill to Its Board of Directors
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure
GlobeNewswireApr 16 21:00
10 Buy-Rated Stocks With Latest Insider Purchases
Yahoo FinanceApr 15 00:52
Needham: Reiterates the Annexon (ANNX.US) rating and adjusted from buy to buy rating, target price is $16.00.
Needham: Reiterates the Annexon (ANNX.US) rating and adjusted from buy to buy rating, target price is $16.00.
Zhitong FinanceApr 11 19:20
No Data
No Data